XCXinyi Chen

Xinyi Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xinyi Chen has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Xianglin Yuan

    Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    15 shared publications
  • Jingyao Tu

    Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

    7 shared publications
  • Lu Wang

    Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    4 shared publications
  • Mu Yang

    Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

    4 shared publications
  • Mu Yang

    Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    4 shared publications
  • Jingyao Tu

    Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    3 shared publications

Latest Publications

  • Open Access

    Interpretable early mortality prediction in oncology ICU patients: A dual-cohort validation of a LASSO–XGBoost–SHAP framework

    by Xinyi Chen, Lu Wang, Wan Qin, Mu Yang, Yuanmei Yan, Xiaoxiao Luo, Xianglin Yuan

    Early risk stratification for critically ill cancer patients remains challenging, and conventional severity scores are frequently miscalibrated. We developed and externally validated an interpretable first-day (0-24 h) risk-reassessment model for ICU mortality during the index ICU stay. We performed a retrospective dual-cohort study using MIMIC-IV for derivation/internal validation (n=9,532; training n=6,673, internal test n=2,859) and eICU-CRD for external validation (n=7,821) among adult cancer patients with an index ICU stay >=24 h. Candidate predictors were restricted to the first 0-24 h after ICU admission. LASSO selected sparse features, nine algorithms were benchmarked, and the final model was chosen by integrated assessment of discrimination, calibration, and decision-curve net benefit. Performance was evaluated using ROC-AUC, PR-AUC, sensitivity, PPV, F2, Brier score, ECE, calibration plots, and decision-curve analysis over p_t=0.01-0.50. TreeSHAP provided global, cohort-level, feature-level, and directional interpretation. ICU mortality rates were 9.45% in MIMIC and 7.39% in eICU. XGBoost was retained as the locked model. In the internal test set, XGBoost achieved ROC-AUC 0.864 (95% CI 0.844-0.885), PR-AUC 0.428, sensitivity 0.807, PPV 0.249, and F2 0.558. In eICU, performance remained stable (ROC-AUC 0.848, 95% CI 0.832-0.864; PR-AUC 0.367; sensitivity 0.794; PPV 0.192; F2 0.487). Calibration remained clinically acceptable, and decision-curve analysis showed positive net benefit across plausible thresholds. SHAP highlighted treatment-intensity indicators and acute physiologic stressors, including vasopressors, sedation, mechanical ventilation, HR_max, SpO2_min, BUN_max, potassium_max, and RR_max, without implying causal effects. This LASSO-XGBoost-SHAP framework supports first-day reassessment after completion of the 24-h predictor window, subsequent monitoring prioritization, resource allocation, and goal-concordant decision-making in oncology ICUs. It should not be interpreted as an admission-time triage model.

  • Open Access

    Visceral Adiposity Index and Cancer Prevalence in U.S. Adults: A Cross-Sectional Analysis of NHANES 1999–2020

    by Xinyi Chen, Mu Yang, Weiheng Zhao, Jingyao Tu, Xianglin Yuan

    Objective: Visceral adiposity has been implicated in carcinogenesis through chronic inflammation, insulin resistance, and lipid dysregulation, whereas body mass index (BMI) does not capture fat distribution. The Visceral Adiposity Index (VAI)—combining waist circumference, BMI, triglycerides, and high-density lipoprotein-cholesterol (HDL-C)—serves as a surrogate of visceral fat function, but its value for cancer risk prediction is unclear. We aimed to evaluate the association between VAI and cancer prevalence in U.S. adults using NHANES 1999–2020, assess independence from BMI, characterize subgroup and dose–response patterns, and conduct prespecified exploratory site-specific analyses. Methods: A total of 20,699 adults aged ≥20 years were included after excluding participants with missing data. The primary outcome was a self-reported history of physician-diagnosed cancer, with the exclusion of non-melanoma skin cancers—such as basal cell carcinoma and squamous cell carcinoma—due to their typically indolent behavior and minimal epidemiological impact. Importantly, melanoma cases were included in the analysis. VAI was analyzed both as a continuous variable and in quartile-based categories (<1.0, 1.0–<2.0, 2.0–<3.0, and ≥3.0). Weighted logistic regression models were constructed with progressive adjustment for demographic, lifestyle, and metabolic covariates (e.g., hypertension, diabetes). Restricted cubic spline (RCS) analyses were performed to assess the dose–response relationship between VAI and cancer, and interaction analyses were conducted across subgroups defined by sex, age, BMI, and hypertension status. Results: In the unadjusted model, each one-unit increase in VAI was associated with significantly higher odds of cancer (OR = 1.019; 95% CI: 1.003–1.035; p = 0.019). Participants in the highest VAI category (≥3.0) had approximately threefold increased odds of cancer compared to those in the lowest category (<1.0) (OR = 3.04; p < 0.001). After stepwise adjustment for demographic and lifestyle factors, the association attenuated; in our prespecified primary model that excluded BMI and hyperlipidemia to avoid overadjustment, the association remained statistically significant (OR = 1.024; 95% CI: 1.004–1.045; p = 0.021), indicating that higher VAI was independently associated with cancer prevalence. RCS analysis suggested a weak, approximately linear increase in cancer prevalence odds with increasing VAI, without a clear threshold effect; the overall association was statistically significant (p = 0.0428), and the test for nonlinearity showed borderline significance (p = 0.0540). Subgroup analyses showed a consistent pattern across most strata, except for a borderline significant interaction by hypertension status (p = 0.044), with a stronger association in individuals without hypertension. In pre-specified site-specific analyses, no individual cancer type demonstrated an independent positive association with VAI after full adjustment; intermediate VAI levels were inversely associated with cervical cancer, a counterintuitive finding that warrants cautious interpretation given limited case counts. Conclusions: Higher VAI levels were associated with increased cancer prevalence; however, the strength of the association diminished after controlling for traditional obesity metrics. These findings suggest that VAI may offer limited independent predictive value for cancer risk beyond BMI. Further prospective and mechanistic studies are warranted to establish causal relationships and evaluate the utility of VAI in identifying high-risk subpopulations.

  • Open Access

    SNHG5 enhances colorectal cancer metastasis through RNA–protein interaction with GNB2 and activation of canonical Wnt signaling

    by Xinyi Chen, Mu Yang, Xiaoxiao Luo, Xianglin Yuan

    Colorectal cancer (CRC) is one of the most prevalent and lethal malignancies worldwide, with distant metastasis—particularly to the liver—representing the primary cause of poor prognosis. Long non-coding RNAs (lncRNAs) have emerged as critical regulators of CRC progression, yet the mechanisms by which they modulate G protein signaling during hepatic metastasis remain unclear. This study aimed to determine the role of the lncRNA SNHG5 in CRC liver metastasis and to explore whether G protein–related mechanisms are involved in this process. We established murine MC38 CRC sublines with distinct metastatic capacities (F0 and F3) and performed RNA sequencing to identify key lncRNAs. Biotin-labeled RNA pull-down coupled with mass spectrometry was used to identify SNHG5-interacting proteins. The SNHG5–GNB2 interaction was validated using RIP, RNA-FISH, and Western blot analyses. Functional rescue assays, in vivo liver metastasis models, and Wnt pathway activity measurements were conducted to delineate downstream effects. Public transcriptomic datasets from GEO and TCGA were used to assess the expression patterns and prognostic relevance of SNHG5 and GNB2 in CRC and metastatic lesions. SNHG5 was significantly upregulated in the highly metastatic F3 subline and predominantly localized in the cytoplasm. Pull-down and proteomic analysis identified GNB2, a classical G protein β-subunit, as a direct binding partner of SNHG5. Functionally, SNHG5 promoted cell proliferation, migration, epithelial–mesenchymal transition (EMT), and suppressed apoptosis, while GNB2 overexpression partially rescued the tumor-suppressive phenotypes induced by SNHG5 silencing. Mechanistically, the SNHG5–GNB2 axis enhanced Wnt/β-catenin signaling via increased p-GSK3β and β-catenin levels, thereby driving EMT. Transcriptomic analyses further revealed that GNB2 is upregulated in CRC and liver metastases and is associated with poor prognosis. Multi-omics data suggested additional roles for this axis in immune evasion, metabolic reprogramming, and remodeling of the metastatic microenvironment. This study provides the first evidence that SNHG5 promotes CRC liver metastasis through direct interaction with GNB2 and subsequent activation of the Wnt/β-catenin pathway. The SNHG5–GNB2 axis orchestrates a multilayered regulatory network that integrates EMT induction, immune suppression, and metabolic adaptation, highlighting its potential as a mechanistic driver and therapeutic target in metastatic CRC.


  • Open Access

    Molecular mechanisms underlying the abscopal effect induced by radiotherapy and its synergistic translational potential with immunotherapy

    by Xinyi Chen, Mu Yang, Yongbiao Huang, Jingyao Tu, Yuwen Cai, Xianglin Yuan

    Abscopal immunity—the regression of distant, non-irradiated lesions after localized radiotherapy (RT)—signals conversion of focal DNA damage into systemic antitumor immunity. This review advances a unifying three-stage framework—initiation, amplification, and reinforcement—explaining how RT can be leveraged to elicit durable systemic control. In initiation, immunogenic cell death and cytosolic DNA activate cGAS–STING (with TLR3–interferon (IFN)-I as a compensatory axis), driving dendritic cell recruitment and cross-priming in tumor-draining lymph nodes. Amplification entails chemokine-guided trafficking and expansion of CXCR3 + cytotoxic T cells, together with stromal and vascular remodeling that enable infiltration at out-of-field sites. Reinforcement reflects the balance between memory formation and adaptive resistance (PD-L1 upregulation, myeloid/Treg accrual, adenosine, and metabolic checkpoints), defining actionable targets for combinatorial intervention. We critically appraise clinical data showing that RT paired with immune-checkpoint inhibition can increase out-of-field control in selected settings, whereas heterogeneous or negative trials underscore the importance of dose and fractionation, field design/target coverage, RT-immune checkpoint inhibitor sequencing, and sparing of lymphoid structures. We outline emerging levers—including spatially fractionated RT, FLASH RT, proton therapy, myeloid- and adenosine-axis blockade, and nanotechnology-enabled in situ vaccination—and candidate biomarkers (interferon-response signatures, circulating tumor DNA kinetics, T-cell clonotypes). Operationalizing these principles points toward making the abscopal effect a predictable, clinically actionable endpoint rather than a rarity.


  • Open Access

    Lactate dehydrogenase-to-albumin ratio as a predictor of 28-day mortality in critically Ill patients with gastrointestinal cancers: Insights from machine learning and the Medical Information Mart for Intensive Care IV database

    by Xinyi Chen, Yuwen Cai, Xianglin Yuan

    Objective: To determine whether the lactate dehydrogenase-to-albumin ratio (LDAR) predicts 28-day mortality in critically ill patients with gastrointestinal (GI) malignancies and to quantify its incremental value in machine learning (ML) models. Methods: We conducted a retrospective cohort study in Medical Information Mart For Intensive Care IV (2008–2019). Adults with GI malignancies who met Sepsis-3 within 24 h of their first intensive care unit (ICU) admission were included. LDAR was computed from laboratory results obtained within 24 h. The primary outcome was 28-day all-cause mortality. Associations were estimated with multivariable logistic regression; nonlinearity was evaluated using restricted cubic splines. Multiple ML classifiers (AdaBoost, XGBoost, random forest) were trained with a 7:3 split and 5-fold cross-validation. Discrimination (area under the curve—AUC), clinical utility (decision-curve analysis), and interpretability (Shapley additive explanation—SHAP) were assessed. Prespecified subgroup analyses stratified by metastatic status and infection site were performed. Covariates included age, sex, weight, vital signs, Sequential Organ Failure Assessment, and metastatic status. Missingness was handled with multiple imputation by chained equations. Results: Among 1177 patients, 28-day mortality was 48.4%. Higher LDAR was independently associated with death; the adjusted odds ratio for Q4 vs Q1 was 5.15 (95% CI 3.52–7.61; P < 0.001). Spline analyses showed a steep risk rise above log2(LDAR) = 5.314 (≈40). Effects were directionally consistent across subgroups with no significant LDAR × metastatic interaction ( P = 0.084) and borderline heterogeneity by infection site ( P = 0.051). The best ML model, AdaBoost, achieved an AUC of 0.835 and yielded the largest net clinical benefit across clinically relevant thresholds. SHAP ranked LDAR among the most influential predictors. Sensitivity analyses using alternative exposure codings produced concordant estimates. Model calibration was acceptable. Conclusion: LDAR is a simple, interpretable, and independently prognostic biomarker for 28-day mortality in ICU patients with GI malignancies. Incorporating LDAR into ML models improved discrimination and decision benefit over conventional severity scores, supporting LDAR-based early risk stratification. External multicenter validation and evaluation of dynamic LDAR trajectories are warranted, and transparent analytic reporting.


  • Open Access

    The MCIB Model: A Novel Theory for Describing the Spatial Heterogeneity of the Tumor Microenvironment

    by Minghao Guo, Yinan Sun, Xiaohui Wang, Zikun Wang, Xun Yuan, Xinyi Chen, Xianglin Yuan, Lu Wang

    The tumor microenvironment (TME) can be regarded as a complex and dynamic microecosystem generated by the interactions of tumor cells, interstitial cells, the extracellular matrix, and their products and plays an important role in the occurrence, progression and metastasis of tumors. In a previous study, we constructed an IEO model (prI-, prE-, and pOst-metastatic niche) according to the chronological sequence of TME development. In this paper, to fill the theoretical gap in spatial heterogeneity in the TME, we defined an MCIB model (Metabolic, Circulatory, Immune, and microBial microenvironment). The MCIB model divides the TME into four subtypes that interact with each other in terms of mechanism, corresponding to the four major links of metabolic reprogramming, vascular remodeling, immune response, and microbial action, providing a new way to assess the TME. The combination of the MCIB model and IEO model comprehensively depicts the spatiotemporal evolution of the TME and can provide a theoretical basis for the combination of clinical targeted therapy, immunotherapy, and other comprehensive treatment modalities for tumors according to the combination and crosstalk of different subtypes in the MCIB model and provide a powerful research paradigm for tumor drug-resistance mechanisms and tumor biological behavior.


  • Top Cited Papers
    Open Access

    Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies

    by Hang Liang, Min Cui, Jingyao Tu, Xinyi Chen

    Osteosarcoma, a malignant bone tumor predominantly affecting children and adolescents, presents significant therapeutic challenges, particularly in metastatic or recurrent cases. Conventional surgical and chemotherapeutic approaches have achieved partial therapeutic efficacy; however, the prognosis for long-term survival remains bleak. Recent studies have highlighted the imperative for a comprehensive exploration of the osteosarcoma immune microenvironment, focusing on the integration of diverse immunotherapeutic strategies—including immune checkpoint inhibitors, tumor microenvironment modulators, cytokine therapies, tumor antigen-specific interventions, cancer vaccines, cellular therapies, and antibody-based treatments—that are directly pertinent to modulating this intricate microenvironment. By targeting tumor cells, modulating the tumor microenvironment, and activating host immune responses, these innovative approaches have demonstrated substantial potential in enhancing the effectiveness of osteosarcoma treatments. Although most of these novel strategies are still in research or clinical trial phases, they have already demonstrated significant potential for individuals with osteosarcoma, suggesting the possibility of developing new, more personalized and effective treatment options. This review aims to provide a comprehensive overview of the current advancements in osteosarcoma immunotherapy, emphasizing the significance of integrating various immunotherapeutic methods to optimize therapeutic outcomes. Additionally, it underscores the imperative for subsequent research to further investigate the intricate interactions between the tumor microenvironment and the immune system, aiming to devise more effective treatment strategies. The present review comprehensively addresses the landscape of osteosarcoma immunotherapy, delineating crucial scientific concerns and clinical challenges, thereby outlining potential research directions.


  • Open Access

    RUNX transcription factors: biological functions and implications in cancer

    by Xinyi Chen, Lu Wang, Mu Yang, Weiheng Zhao, Jingyao Tu, Bo Liu, Xianglin Yuan

    Runt-related transcription factors (RUNX) are a family of transcription factors that are essential for normal and malignant hematopoietic processes. Their most widely recognized role in malignancy is to promote the occurrence and development of acute myeloid leukemia. However, it is worth noting that during the last decade, studies of RUNX proteins in solid tumors have made considerable progress, suggesting that these proteins are directly involved in different stages of tumor development, including tumor initiation, progression, and invasion. RUNX proteins also play a role in tumor angiogenesis, the maintenance of tumor cell stemness, and resistance to antitumor drugs. These findings have led to the consideration of RUNX as a tumor biomarker. All RUNX proteins are involved in the occurrence and development of solid tumors, but the role of each RUNX protein in different tumors and the major signaling pathways involved are complicated by tumor heterogeneity and the interacting tumor microenvironment. Understanding how the dysregulation of RUNX in tumors affects normal biological processes is important to elucidate the molecular mechanisms by which RUNX affects malignant tumors.


  • Integrated bioinformatics and validation reveal SOX12 as potential biomarker in colon adenocarcinoma based on an immune infiltration-related ceRNA network

    by Xinyi Chen, Mu Yang, Jingyao Tu, Xianglin Yuan

    Purpose The primary objective of this study was to construct competing endogenous RNA (ceRNA) networks and evaluate the prognostic significance of tumor-infiltrating immune cells (TIICs) and key biomarkers within the ceRNA networks in colon adenocarcinoma (COAD) patients. Methods Comprehensive bioinformatics tools were used to screen differentially expressed genes (DEGs), miRNAs (DEMs), and lncRNAs (DELs) related to COAD, leading to the creation of ceRNA networks. The CIBERSORT technique was employed to assess the significance of TIICs in COAD, and an immune-related prognosis prediction model was subsequently developed. Co-expression analyses were conducted to determine the relationship between key genes in ceRNA networks and immunologically significant TIICs. The study also utilized 5 GEO datasets and web-based databases to externally validate the findings. Results The study revealed a statistically significant relationship between key hub genes and immune cells, as determined through co-expression analysis. Two hub regulators (SOX12 and H19) demonstrated significant prognostic value in the ceRNA-related prognostic model, and their elevated expression levels were verified across multiple CRC cell lines. Additionally, the knockdown of SOX12 led to a suppression of proliferation, migration, and invasion in colon cancer cells. Conclusion Through the construction of ceRNA networks and evaluation of TIICs, the study successfully established two risk score models and nomograms. These models serve as valuable tools for understanding the molecular processes and predicting the prognosis of COAD patients. Further validation of hub regulators SOX12 and H19 substantiates their potential role as key biomarkers in COAD.


  • Open Access

    The application and research progress of anti-angiogenesis therapy in tumor immunotherapy

    by Jingyao Tu, Hang Liang, Chunya Li, Yongbiao Huang, Ziqi Wang, Xinyi Chen, Xianglin Yuan

    Tumor immunotherapy, as the focus of scientific research and clinical tumor treatment in recent years, has received extensive attention. Due to its remarkable curative effect and fewer side effects than traditional treatments, it has significant clinical benefits for the treatment of various advanced cancers and can improve cancer patient survival in the long term. Currently, most patients cannot benefit from immunotherapy, and some patients may experience tumor recurrence and drug resistance even if they achieve remission overcome. Numerous studies have shown that the abnormal angiogenesis state of tumors can lead to immunosuppressive tumor microenvironment, which affects the efficacy of immunotherapy. Actually, to improve the efficacy of immunotherapy, the application of anti-angiogenesis drugs to normalize abnormal tumor vessel has been widely confirmed in basic and clinical research. This review not only discusses the risk factors, mechanisms, and effects of abnormal and normalized tumor angiogenesis state on the immune environment, but summarizes the latest progress of immunotherapy combined with anti-angiogenic therapy. We hope this review provides an applied reference for anti-angiogenesis drugs and synergistic immunotherapy therapy.